Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 358570Orphan Drug1 approvals5 trials

GI Innovation Inc.

Official website

Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.

As of 2026-10-11, GI Innovation Inc. has 16 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2017 and listed on KOSDAQ in 2023, GI Innovation is a biotech company developing next-generation immunotherapies based on fusion protein technology. Its core pipeline includes the immuno-oncology candidates GI-101 and GI-102, the allergy treatment GI-301, and the metabolic immuno-oncology candidate GI-108, discovered and produced through its proprietary GI-SMART™ platform (SMART-Selex™ and SMART-cLego™). The company has completed three global licensing deals, including GI-101 to China's Simcere Pharmaceutical for USD 790 million, GI-301 to Yuhan Corporation for KRW 1,409 billion (global rights excluding Japan) plus a further USD 221 million Japan-rights deal in October 2023, along with a co-development clinical agreement with MSD (Merck & Co.).

Regulatory approvals

1 Orphan Drug designations · 2025

  • OrphanGI-102(CD80-IgG4 Fc-IL2v3)2025-01-15
    Orphan Drug designation · in development20240237740

Clinical trials

data.go.kr

5 MFDS clinical trial authorisations · 2021–2026 (Phase 1/2 3 · Phase 2a 1 · Phase 1/2a 1)

  • Phase 1/2GI-1022026-05-29

    2 trial sites

  • Phase 2aGI-1022026-02-23

    1 trial site

  • Phase 1/2aGI-1082024-12-11

    3 trial sites

  • Phase 1/2GI-1022023-02-20

    6 trial sites

  • Phase 1/2GI-1012021-04-21

    9 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

GI-101 · 면역항암 · 임상 · Selected for a KRW 7 billion clinical program grant from the Korea Drug Development Fund (KDDF) and named to the 2020 National R&D Excellence 100 list.

GI-102 · 면역항암 · 임상 · Selected for a KRW 6.4 billion clinical program grant from the Korea Drug Development Fund (KDDF).

GI-301 · 알레르기 · 임상 · Licensed out global rights excluding Japan to Yuhan Corporation at the preclinical stage, followed by an additional licensing deal for Japan development and commercialization rights in October 2023.

GI-108 · 대사면역항암 · 임상 · Selected for a KRW 2 billion preclinical program grant from the Korea Drug Development Fund (KDDF).

Key disclosures

KRX KIND via OpenDART
Show 32 more events

Publications

PubMed · affiliation-matched
Show 6 more publications

Patents

KIPRIS · applicant-matched
Show 124 more patents

AI reads

MAA server logs · IP-verified
127
Times AI engines pulled GI Innovation Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

125
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 1
Last 7 days
61
live 2
Last 30 days
127
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot73
  • GoogleGoogleOther44
  • PerplexityPerplexityBot5
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for GI Innovation Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · products. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition